Vantage logo

A new reality for Immunocore

A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.

Vantage logo

Bristol joins the pharma buyers club

An analysis of EvaluatePharma data shows that, in a Bristol-Myers Squelgene world, all big pharmas are increasing their reliance on external projects.